Oxford vaccine has 70 per cent efficacy

Published:Monday, 23 Nov 2020 07:11

Oxford vaccine has 70 per cent efficacy

The coronavirus vaccine developed by the University of Oxford can stop 70 per cent of people developing Covid symptoms.

The coronavirus vaccine can also prevent from getting Covid-19 up to 90 percent if a lower dose is used, according to data.

Oxford University and AstraZeneca have announced their jab is effective in preventing many people getting ill and it has been shown to work in different age groups, including the elderly.

There are early indications it might also help stop the spread of the disease.

Sarah Gilbert, professor of vaccinology at the University of Oxford, said: “The announcement today takes us another step closer to the time when we can use vaccines to bring an end to the devastation caused by [Covid-19].

“We will continue to work to provide the detailed information to regulators. It has been a privilege to be part of this multi-national effort, which will reap benefits for the whole world.”

Oxford University said interim analysis from its phase 3 vaccine trial showed that the efficacy of their vaccine is 70%. But that came from combining the results of two different dosing regimes, one of which was 90% and the other was 62%. The 90% regime involved a half-dose first and then a full dose of the vaccine later.

In a statement, Prof Andrew Pollard, the director of the Oxford Vaccine Group and chief investigator of the Oxford vaccine trial, said: “These findings show that we have an effective vaccine that will save many lives. Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply.